N Acetylcysteine in Bronchiectasis.

N Acetylcysteine in Adults with Bronchiectasis: A feasibility pilot study assessing, anti-inflammatory and clinical effects.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12621001013853

Acronym

nil

Enrollment

Registered

2021-08-04

Start date

2018-09-30

Completion date

2021-11-01

Last updated

2021-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This pilot study aims to examine the anti-inflammatory and clinical effects of oral N acetylcysteine( 2400 mg/day) in bronchiectasis over a 6 week period compared with placebo.We hypothesise it will improve these outcomes.

Interventions

N acetylcysteine capsules 600mg 2 tablets morning and night for 6 weeks

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

bronchiectasis

Exclusion criteria

current smokers, those with greater than 20 pack year history, cystic fibrosis, non tuberculous mycobacterial infection.

Outcome results